MBX Biosciences offers a catalyst-rich, high-risk/high-upside biotech profile built on precision peptide chemistry, a Phase 3-ready once-weekly hypoparathyroidism therapy, and potentially differentiated once-monthly obesity assets.
Overview
MBX Biosciences is a pre-revenue clinical-stage biotech developing precision peptide therapies for endocrine and metabolic diseases through its proprietary PEP™ platform. Its lead asset, once-weekly canvuparatide, is Phase 3-ready for chronic hypoparathyroidism, while MBX 4291 and MBX 5765 target obesity with potential once-monthly dosing. The company has no commercial revenue today, but targets high-value orphan and massive obesity markets. Its differentiation is built around programmable peptide prodrugs that extend half-life, stabilize drug exposure, reduce adverse effects, and improve patient convenience versus daily or weekly alternatives.